About Theravance biopharma us, inc.
Theravance Biopharma US, Inc. is a biopharmaceutical company that focuses on the discovery and development of organ-selective medicines to treat serious diseases. The company's mission is to transform the treatment of these diseases by developing innovative therapies that target specific organs or tissues in the body.
The company was founded in 2014 as a spin-off from Theravance, Inc., a biopharmaceutical company that focused on respiratory disease treatments. Theravance Biopharma US, Inc. has since expanded its focus to include other therapeutic areas such as gastrointestinal disorders and immunology.
One of the key strengths of Theravance Biopharma US, Inc. is its proprietary drug discovery platform called "Multivalent Drug Design" (MDD). This platform allows for the creation of highly selective drugs that target specific organs or tissues in the body while minimizing side effects on other parts of the body.
Theravance Biopharma US, Inc.'s pipeline includes several promising drug candidates in various stages of development. One such candidate is TD-1473, an oral gut-selective pan-Janus kinase (JAK) inhibitor being developed for inflammatory bowel disease (IBD). Another candidate is TD-8236, an inhaled lung-selective pan-JAK inhibitor being developed for chronic obstructive pulmonary disease (COPD).
In addition to its internal drug development programs, Theravance Biopharma US, Inc. also collaborates with other companies and academic institutions to advance its research efforts. For example, it has partnered with Janssen Pharmaceuticals to develop TD-1473 for IBD and with Mylan N.V. to develop revefenacin for COPD.
Theravance Biopharma US, Inc.'s commitment to innovation and excellence has been recognized by numerous awards and accolades over the years. In 2019 alone, it was named one of Deloitte's Technology Fast 500™ companies and received two awards from BioPharm America™: "Licensing Deal of the Year" and "Innovation Award".
Overall, Theravance Biopharma US, Inc.'s dedication to developing organ-selective medicines represents a significant step forward in treating serious diseases more effectively while minimizing side effects on other parts of the body. With its cutting-edge technology platform MDD and strong pipeline of drug candidates across multiple therapeutic areas, this biotech firm is poised for continued success well into the future.
In conclusion,Theravance Biopharma aims at transforming how we treat serious illnesses through their innovative approach towards discovering new drugs which are organ-specific thus reducing any possible side effects associated with traditional medication.Therapeutic areas covered include respiratory diseases,gastrointestinal disorders,and immunology.Their Multivalent Drug Design(MDD)platform enables them create highly selective drugs targeting specific organs or tissues within our bodies.Their pipeline includes promising candidates like TD-1473 which targets inflammatory bowel disease(IBD),and TD-8236 which targets chronic obstructive pulmonary disease(COPD).Their collaborations with Janssen Pharmaceuticals,and Mylan N.V have enabled them advance their research efforts further.In recognition,TBU has received numerous awards including Deloitte's Technology Fast 500™ companies award,and two BioPharm America™ awards;the Licensing Deal Of The Year award,and Innovation Award respectively.With TBU's commitment towards innovation,it will continue making strides towards revolutionizing how we treat serious illnesses through their cutting-edge technology platform MDD coupled up with their strong pipeline across multiple therapeutic areas making them stand out among competitors within this industry
theravance.com
